The Stakeholder Engagement Manual Volume 2 - AccountAbility

More documents

Recommendations

Info

STAGE 1 SUGGESTED METHODOLOGY M1: MAPPING YOUR STAKEHOLDERS Th e purpose of this activity is to ensure that, as far as possible, all relevant stakeholders are identifi ed. Convene a cross-functional group of people who have broad knowledge about the organisation, project, department or even specifi c issue that you want to identify the stakeholders for. Th ese could include, but are not limited to, people from the legal department, risk management, external communications, procurement, EHS, HR, and investor relations. You could also involve external consultants and specialists. Brainstorm a list of stakeholder categories using the three dimensions outlined below (Depending on size of group you may want to do this in pairs or small groups before sharing conclusions as a wall display) SUMMARY TEMPLATE T1: MAPPING STAKEHOLDERS* Stakeholders who are affected by your organisation's operations. *electronic version downloadable at www.accountability.org.uk People you have legal, fi nancial or operational responsibilities to. People who are likely to infl uence your organisation's performance (those with infl uence and decision makers) THE PRACTITIONER'S HANDBOOK ON STAKEHOLDER ENGAGEMENT | 25
Analyse and Plan the Engagement P1: MAPPING YOUR STAKEHOLDERS Stakeholder Category Employee Investors Customers Suppliers Group the stakeholders into categories (you may want to use the generic categories highlighted above, or use your own categories) and subgroups likely to share similar perspectives. For example “Non-governmental Organisations” might include humanitarian organisations, human rights organisations, animal welfare groups and environmental groups. Th is further diff erentiation is of critical importance, as this is where stakeholder identifi cation becomes meaningful and detailed enough to decide on their materiality and possible next steps. See examples below: This is a high level stakeholder map developed by a UK pharmaceutical company Sub-groups Board and executive team Management Staff Trade unions New recruits Potential recruits Employees who have left the company Institutional investors Pension funds Fund managers and analysts Rating agencies Socially responsible investment movement National Health Service Trusts Doctors Patients Private clinics Hospitals Pharmacists Wholesalers Prescription infl uences (e.g. nurses, social workers, teachers, psychologist) Internal clients Suppliers of materials and ingredients Contract manufacturers Doctors (as R&D consultants) Clinical trial centres Volunteers and patients in trials Service providers and infrastructure products Stakeholder Category Competitors Government and Regulators Business Partners Local Communities Academia and Scientifi c Community Media NGOs and Pressure Groups Sub-groups Pharmaceutical companies Biotech companies Department of Health Pharmaceutical regulatory authorities Food and Drug Administration (US) World Health Organization (UN) Licensees R&D partners Other pharmaceutical companies Clinics/universities Neighbours Local authorities/ Planning Department Charities and voluntary organisations Environmental groups University centres Researchers Students TV and Radio Medical/scientifi c publications National/local newspapers Financial newspapers Patient organisations Human rights organisations Animal welfare organisations Environmental organisations Alternative medicine associations
Page 1: VOLUME 2
Page 4 and 5: Forewords Foreword by AccountAbilit
Page 6 and 7: Contents WELCOME STAGE 1 STAGE 2 ST
Page 8 and 9: Introduction OPENING NOTE Backgroun
Page 10 and 11: Introduction WHY ENGAGE? Th e past
Page 12 and 13: Introduction WHAT IS IN THIS HANDBO
Page 14 and 15: Forwards Introduction HOW TO USE TH
Page 16 and 17: Introduction PRINCIPLES AND STANDAR
Page 18 and 19: Introduction PRINCIPLES AND STANDAR
Page 20 and 21: Introduction PROCESS SUMMARY STAGE
Page 22 and 23: Introduction BEFORE YOU START Befor
Page 24 and 25: Think Strategically STAGE 1 PURPOSE
Page 26 and 27: STAGE 1 Th e process outlined in th
Page 30 and 31: Camelot's Eight Stakeholder Groups
Page 32 and 33: New obligations Public Scrutiny New
Page 34 and 35: Awareness and Preparedness for Emer
Page 36 and 37: STAGE 1 • Identify Strategic Enga
Page 38 and 39: P3: IDENTIFYING ISSUES A B C D E ST
Page 40 and 41: ‘What we know’ ‘What they tel
Page 42 and 43: STAGE 1 THINGS TO CONSIDER This is
Page 44 and 45: Latent Emerging The Four Stages of
Page 46 and 47: Stakeholder dependence on the organ
Page 48 and 49: High impact stakeholder groups are
Page 50 and 51: KEY PRIORITIES Sales, players and w
Page 52 and 53: STAGE 2 Take time to analyse and pl
Page 54 and 55: Analyse and Plan PRINCIPLES Th e ke
Page 56 and 57: Analyse and Plan P5: REVIEWING YOUR
Page 58 and 59: Analyse and Plan P5: REVIEWING YOUR
Page 60 and 61: Analyse and Plan P6: LEARNING FROM
Page 62 and 63: Analyse and Plan P6: LEARNING FROM
Page 64 and 65: Analyse and Plan P7: ASSESSING YOUR
Page 70 and 71: Analyse and Plan P8: UNDERSTANDING
Page 76 and 77: Analyse and Plan P9: CHECKING FOR R
Page 78 and 79:
Analyse and Plan P9: CHECKING FOR R
Page 80 and 81:
Analyse and Plan P10: CREATING AN I
Page 83 and 84:
STAGE 3 Maintain and strengthen the
Page 85 and 86:
Strengthen Capacities for Engagemen
Page 87 and 88:
Page 89 and 90:
Page 91 and 92:
Page 93 and 94:
Page 95 and 96:
Page 97 and 98:
Page 99 and 100:
Engage with your stakeholders in wa
Page 101 and 102:
How this Stage relates to the other
Page 103 and 104:
Level Remain Passive Monitor Inform
Page 105 and 106:
STAGE 4 • Use the table, as well
Page 107 and 108:
Telephone Hotlines (continued) One-
Page 109 and 110:
STAGE 4 Involving Stakeholders in I
Page 111 and 112:
Stakeholder Advisory or Assurance P
Page 113 and 114:
12 Offi ce of Consumer Affairs “V
Page 115 and 116:
Name Common Facilitation Techniques
Page 117 and 118:
STAGE 4 Outcomes and process planni
Page 119 and 120:
British American Tobacco Uses Indep
Page 121 and 122:
STAGE 4 Article 13's Method of Asse
Page 123:
STAGE 4 REVIEW STAGE 4 By the end o
Page 126 and 127:
Take action and review the engageme
Page 128 and 129:
P16: CREATING A PLAN FOR ACTION STA
Page 130 and 131:
Strategic Objective STAGE 5 THINGS
Page 132 and 133:
Camelot's Performance Reporting STA
Page 134 and 135:
BAT's Reporting on Stakeholder Dial
Page 136 and 137:
STAGE 5 SUGGESTED METHODOLOGY M17:
Page 138 and 139:
Thinking about Assurance (continued
Page 140 and 141:
Engagement Process SUMMARY TEMPLATE
Page 142 and 143:
ANNEX
Page 144 and 145:
Annex JARGON BUSTER JARGON BUSTER 1
Page 146 and 147:
Annex FURTHER RESOURCES & BIBLIOGRA
Page 148 and 149:
Annex Interact Network: Framework f
Page 150 and 151:
Annex FURTHER ACKNOWLEDGEMENTS In a
Page 152 and 153:
Annex ACCOUNTABILITY AccountAbility
Page 154:
Annex STAKEHOLDER RESEARCH ASSOCIAT
show all

The Stakeholder Engagement Manual Volume 2 - AccountAbility

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?